TLR4 and infection: Altogether, these results indicate that the cytokine and chemokine response could be elicited by the α-Gal vaccine plus the adjuvant LMPLA, which is a strong activator of Toll-like receptor 4-mediated signaling pathway65,79 and not by the carrier protein HSA or adjuvant alone, thus modulating an effective protective host immune defense against infection.